Evidence map›Paper›PMID 39682197›Full record

ArticleCancers2024

FoxP3

Eva Erzar, Alexandar Tzankov, Janja Ocvirk, Biljana Grčar Kuzmanov, Lučka Boltežar, Veronika Kloboves Prevodnik, Gorana Gašljević

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eva ErzarDepartment of Cytopathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.ORCID 0009-0005-8230-8707
Alexandar TzankovPathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Schönbeinstrasse 40, 4031 Basel, Switzerland.ORCID 0000-0002-1100-3819
Janja OcvirkMedical Faculty, University of Ljubljana, Vrazov Trg 2, 1000 Ljubljana, Slovenia.ORCID 0000-0002-5235-2054
Biljana Grčar KuzmanovDepartment of Pathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.
Lučka BoltežarMedical Faculty, University of Ljubljana, Vrazov Trg 2, 1000 Ljubljana, Slovenia.ORCID 0000-0001-7280-1470
Veronika Kloboves PrevodnikDepartment of Cytopathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.ORCID 0000-0002-0605-6596
Gorana GašljevićDepartment of Pathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.ORCID 0000-0002-8332-3627

Funding

Slovenian Research and Innovation Agency (ARIS) P3-0289
6 · The paper itself

Abstract

BACKGROUND/

objectivesThe tumour microenvironment (TME) plays an important role in the development and progression of cancer and it differs among lymphomas, both with respect to the composition and quantity of specific tumour-infiltrating immune cells (TICs), such as FoxP3

methodsexcisional lymph node (LN) biopsies from 105 nodal PTCLs and 17 reactive LNs are immunohistochemically stained for FoxP3. Visual scoring of FoxP3

resultsFoxP3

conclusionsthese findings underscore the promise of FoxP3

Indexed as

cut-off valueFoxP3+overall survivalperipheral T-cell lymphomaprognostic biomarkerregulatory T cells

Identifiers

PMID39682197
PMCPMC11640135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.